Inhibitory efficacy of intravitreal dexamethasone acetate-loaded plga nanoparticles on choroidal neovascularization in a laser-induced rat model

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 6, 2007, Pages 527-539

  Xu, Jianfeng ^a   Wang, Yusheng ^a   Li, Yue ^a   Yang, Xiumei ^a   Zhang, Peng ^a   Hou, Huiyuan ^a   Shi, Yuanyuan ^a   Song, Chunxian ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE ACETATE; NANOPARTICLE; POLYGLACTIN; PREDNISOLONE ACETATE;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; ELECTRORETINOGRAPHY; EMULSION; EVAPORATION; EYE FUNDUS; EYE INFLAMMATION; EYE TOXICITY; HISTOLOGY; IN VITRO STUDY; INCIDENCE; LASER; LASER COAGULATION; MALE; NONHUMAN; RAT; RETINA; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RODENT; SUBRETINAL NEOVASCULARIZATION; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; ELECTRORETINOGRAPHY; GLYCOLATES; INJECTIONS; LASER COAGULATION; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, INBRED BN; TIME FACTORS; VITREOUS BODY;

EID: 36749059610     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0002     Document Type: Article

References (53)

1. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv. Ophthalmol. 39:367-374, 1995.
2. O'Shea, J.G. Age-related macular degeneration: A leading cause of blindness. Med. J. Aust. 165:561-564, 1996.
3. Cohen, S.Y., Laroche, A., Leguen, Y., et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241-1244, 1996.
4. Sickenberg, M., Schmidt-Erfurth, U., Miller, J.W., et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch. Ophthalmol. 118:327-336, 2000.
5. D'Amore, P.A. Mechanisms of retinal and choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 35:3974-3979, 1994.
6. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of agerelated macular degeneration: Updated findings from two clinical trials. Arch. Ophthalmol. 111:1200-1209, 1993.
7. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Treatment of age-related macular degeneration with photodynamic therapy neovascularization in age-related macular degeneration with verteporfin: One-year results of two randomized clinical trials - TAP report 1. Arch. Ophthalmol. 117:1329-1345, 1999.
8. Stokkermans, T.J. Treatment of age-related macular degeneration. Clin. Eye Vis. 12:15-35, 2000.
9. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alpha-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Arch. Ophthalmol. 115:865-872, 1997.
10. Bhisitkul, R.B. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br. J. Ophthalmol. 90:1542-1547, 2006.
11. Killingsworth, M.C., Sarks, J.P., Sarks, S.H. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye 4:613-621, 1990.
12. Dastgheib, K., and Green, W.R. Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch. Ophthalmol. 112:813-818, 1994.
13. Oh, H., Takagi, H., Tagaki, C., et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 40:1891-1898, 1999.
14. Kvanta, A., Algvere, P.V., Berglin, L., et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37:1929-1934, 1996.
15. Proia, A.D., Harakata, A., McInnes, J.S., et al. The effect of angiostatic steroids and beta-cylodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res. 57:693-698, 1993.
16. Edelman, J.L., Castro, M.R., and Wen, Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest. Ophthalmol. Vis. Sci. 40:1112-1123, 1990.
17. Rotschild, T., Nandgaonkar, B.N., and Yu, K. Dexamethasone reduces oxygen-induced retinopathy in a mouse model. Pediatr. Res. 46:94-100, 1999.
18. Ishibashi, T., Miki, K., Sorgente, N., et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch. Ophthalmol. 103:708-711, 1985.
19. Castronovo, V., and Belotti, D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur. J. Cancer 14:2520-2527, 1996.
20. Jain, R.A., Rhodes, C.T., Railkar, A.M., et al. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: Effect of various formulation variables. Eur. J. Pharm. Biopharm. 50:257-262, 2000.
21. Duvvuri, S., Janoria, K.G., and Mitra, A.K. Development of a novel formulation containing poly(D,L-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J. Contr. Rel. 108:282-293, 2005.
22. Anderson, J.M., and Shive, M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28;5-24, 1997.
23. Song, C., Labhasetwar, V., Murphy, H., et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J. Contr. Rel. 43:197-212, 1997.
24. Ciulla, T.A., Criswell, M.H., Danis, R.P., et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. 119:399-404, 2001.
25. El Braney, M., Cheng, L., Bartsch, D.U., et al. Preventive versus treatment effect of Ag3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization. J. Ocul. Pharmacol. Ther. 20:217-236, 2004.
26. Ciulla, T.A., Criswell, M.H., Danis, R.P., et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. 87:1032-1037, 2003.
27. Okabe, K., Kimura, H., Okabe, J., et al. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. 44:2702-2707, 2003.
28. Takehana, Y., Kurokawa, T., Kitamura, T., et al. Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest. Ophthalmol. Vis. Sci. 40:459-466, 1999.
29. Edelman, J.L., and Castro, M.R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 71:523-533, 2000.
30. Ogata, N., Matsushima, M., Takada, Y., et al. Expression of basic fibroblast growth factor mRNA in developing choroidal neovascularization. Curr. Eye Res. 15:1008-1018, 1996.
31. Shen, W., Yu, M., Barry, C., et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularization in the rat. Br. J. Ophthalmol. 82:1063-1071, 1998.
32. Wada, M., Ogata, N., Otsuji, T.U., et al. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr. Eye Res. 18:203-213, 1999.
33. Ogata, N., Yamamoto, C., Miyashiro, M., et al. Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization. Curr. Eye Res. 16:9-18, 1997.
34. Tobe, T., Takahashi, K., Ohkuma, H.U., et al. A long-term course of experimentally produced choroidal neovascularization in the rat. Nippon Ganka Gakkai Zasshi 99:784-791, 1995.
35. Schmidt-Erfurth, U., Schlötzer-Schrehard, U., Cursiefen, C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 44:4473-4480, 2003.
36. Kent, D., and Sheridan, C. Choroidal neovascularization a wound-healing perspective. Mol. Vis. 9:747-755, 2003.
37. Penfold, P.L., Wong, J.G., Gyory, J., et al. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin. Exp. Ophthalmol. 29:188-192, 2001.
38. Folkman, J., and Ingber, D.E. Angiostatic steroids: Method of discovery and mechanism of action. Ann. Surg. 206:374-383, 1987.
39. Bandi, N., and Kompella, U.B. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur. J. Pharmacol. 425:109-116, 2001.
40. Wang, Y.S., Friedrichs, U.W., Hoffmann, E.S., et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefe's Arch. Clin. Exp. Ophthalmol. 240:42-48, 2002.
41. Penfold, P.L., Wen, L., Madigan, M.C., et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line implications for macular degeneration. Clin. Exp. Immunol. 121:458-465, 2000.
42. Nauck, M., Karakiulakis, G., Perruchoud, A.P., et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 341:309-315, 1998.
43. Labhasetwar, V. Nanoparticles for drug delivery. Pharm. News 4:28-31, 1997.
44. Shive, M.S., and Anderson, J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28:5-24, 1997.
45. Siepmann, J., and Göpferich, A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv. Drug Deliv. Rev. 48:229-247, 2001.
46. Yang, Z., Birkenhauer, P., Julmy, F., et al. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J. Contr. Rel. 60:269-277, 1999.
47. Li, X., Deng, X., and Huang, Z. In vitro protein release and degradation of poly-dl-lactide-poly (ethylene glycol) microspheres with entrapped human serum albumin: Quantitative evaluation of the factors involved in protein release phases. Pharm. Res. 18:117-124, 2001.
48. Kai, W., Yanrong, J., and Xiaoxin, L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefe's Arch. Clin. Exp. Ophthalmol. 244:1152-1159, 2006.
49. Wiechens, B., Neumann, D., Grammer, J.B., et al. Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int. Ophthalmol. 22:133-143, 1999.
50. Lopez-Cortes, L.F., Pastor-Ramos, M.T., Ruiz-Valderas, R., et al. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 42:1024-1028, 2001.
51. Gillies, M.C., Simpson, J.M., Billson, F.A., et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized, clinical trial. Arch. Ophthalmol. 122:336-340, 2004.
52. Jonas, J.B., Degenring, R., Kreissig, I., et al. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am. J. Ophthalmol. 138:1054-1055, 2004.
53. Rechtman, E., Danis, R.P., Pratt, L.M., et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age-related macular degeneration. Br. J. Ophthalmol. 88:344-347, 2004.